CoChat

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease

Open access
Bliederhaeuser, Corinna, Zondler, Lisa, Grozdanov, Veselin, Ruf, Wolfgang P., Brenner, David, Melrose, Heather L., Bauer, Peter, Ludolph, Albert C., Gillardon, Frank, Kassubek, Jan, Weishaupt, Jochen H., Danzer, Karin M. · 2016 · Acta Neuropathologica Communications
Cited by 37

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of familial Parkinson’s disease (PD) [20, 32]. Common polymorphisms in LRRK2 have been shown to modulate the risk for sporadic PD [6, 23, 24] strengthening the idea that inherited and sporadic PD share common underlying pathways. Although LRRK2 has been associated with a variety of cellular functions, including autophagy [1], mitochondrial function/dynamics [30] and microtubule/cytoskeletal dynamics [12], the overall physiological function of LRRK2 and its role in PD are only partially understood. Relatively recent studies also support a role for LRRK2 as regulator of inflammation. Substantial levels of LRRK2 protein and mRNA have been reported in immune cells like peripheral blood mononuclear cells (PBMCs), including B-cells, monocytes/macrophages, and dendritic cells [9, 13, 16, 29]. Moreover, LRRK2 has been shown to be involved in the activation and maturation of immune cells [29], in controlling the radical burst against pathogens in macrophages [9] and in modulating neuroinflammation by cytokine signaling [10, 19]. Remarkably, elevated levels of serum cytokines (IL-2, IL-4, IL-6, IL-10, TNFα) in PD patients [4, 22, 27] point to an involvement of the peripheral immune system in the pathogenesis of PD. Recently, we found an enrichment of “classical” CD14CD16 monocyte subpopulation in the peripheral blood of PD patients together with a dysregulation of inflammatory pathways, phagocytosis deficits as well as hyperactivation of PD monocytes in response to LPS treatment, which correlated to PD severity [11]. Here, we sought to study the contribution of LRRK2 to the dysregulation of monocytes in Parkinson’s disease. We set out to obtain a comprehensive picture of LRRK2 levels in circulating monocyte subpopulations as well as in lymphoid B-cells in PD patients. To determine the intracellular LRRK2 protein levels in the different immune cells we established a flow cytometry-based technique for intracellular LRRK2 staining. To verify the specificity of the anti-LRRK2 antibody used in this study [Novus Biologicals (NB300-268AF647)] isolated murine spleen cells from LRRK2 knockout (KO) mice [14] and mice overexpressing human wild-type (WT) LRRK2 (LRRK2 WT-OX mice) [17, 28] were processed, stained and analyzed as described in the supplementary material and method section (Additional file 1). While we found a highly LRRK2-positive population with the Novus antibody in spleen samples of LRRK2 WT-OX mice (black histogram Fig. 1a) no unspecific staining was found in LRRK2 KO mice (dark grey histogram Fig. 1a) or with the isotype control (IgG ctrl.) in spleen samples of LRRK2 WT-OX mice (light grey histogram Fig. 1a). We used a combination of our well established five-color FACS analysis strategy [5, 11] to distinguish “classical” CD14CD16 (hereinafter referred to as CD14) monocytes and “non-classical” CD14CD16 (hereinafter referred to as CD16) monocytes together with the intracellular LRRK2 staining. We found that both monocyte subpopulations were LRRK2 positive (orange histograms Fig. 1b), while the IgG and unstained controls did not show any significant staining (dark and light grey histograms Fig. 1b). Strikingly, we found significantly higher LRRK2 protein levels in CD16 monocytes (upper panel Fig. 1c) as well as in CD14 monocytes (lower panel Fig. 1c) of PD patients (n = 26; mean age 71.0 years) compared to ageand sex matched healthy controls (n = 26; mean age 68.7 years). Of note, * Correspondence: karin.danzer@uni-ulm.de Department of Neurology, Ulm University, Albert Einstein Allee 11, 89081 Ulm, Germany Full list of author information is available at the end of the article

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-016-0396-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 37

Metadata

Authors
Bliederhaeuser, C., Zondler, L., Grozdanov, V., Ruf, W. P., Brenner, D., Melrose, H. L., Bauer, P., Ludolph, A. C., Gillardon, F., Kassubek, J., Weishaupt, J. H., & Danzer, K. M.
Venue
Acta Neuropathologica Communications
Published
2016-11-24
Volume
4
Issue
1
Pages
123-123
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2550954689
Cited by
37
References
5
FWCI
1.72
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LRRK2 contributes to monocyte dysregulation in Parkinson’s disease. https://app.cochat.ai/papers/10.1186/s40478-016-0396-2
The paper
Bliederhaeuser, C., Zondler, L., Grozdanov, V., Ruf, W. P., Brenner, D., Melrose, H. L., Bauer, P., Ludolph, A. C., Gillardon, F., Kassubek, J., Weishaupt, J. H., & Danzer, K. M. (2016). LRRK2 contributes to monocyte dysregulation in Parkinson’s disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-016-0396-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.